aod9604 fat loss studies AOD-9604 Peptide What Do Clinical Trials Indicate

Simultaneously, higher S-adenosylmethionine (SAM) availability supports key methylation-dependent pathways, which are crucial for epigenetic regulation and gene expression related to energy metabolism

Research has examined the relationship between NNMT activity and metabolic syndrome parameters

Mood changes

As a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, it may surpass even tirzepatide for weight loss based on early clinical data

AOD-9604 works entirely at the fat cell level through beta-3 adrenergic receptor activation

However, further studies are still needed to optimize its clinical application, including dosage form improvement, combination therapy strategies and long-term safety assessment